BioLineRx (NASDAQ:BLRX – Get Free Report) posted its quarterly earnings data on Monday. The biotechnology company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.62), Zacks reports. BioLineRx had a negative return on equity of 32.91% and a negative net margin of 502.08%.The company had revenue of $0.29 million for the quarter, compared to the consensus estimate of $0.50 million.
Here are the key takeaways from BioLineRx’s conference call:
- GLIX1 clinical trial progressing on plan: The Phase I/IIa study in glioblastoma began dosing its second of five planned cohorts, with the third expected to start in September; management reported encouraging safety and tolerability and still expects Phase I data in the first half of 2027.
- New preclinical results showed strong GLIX1 activity in glioblastoma models, including a temozolomide-resistant model, while a low-dose GLIX1–olaparib combination produced substantially better results than either monotherapy in an HR-proficient ovarian cancer model. The company plans an ovarian cancer expansion cohort and has begun discussions with PARP inhibitor developers.
- The CheMo4METPANC Phase IIb pancreatic cancer trial of motixafortide, cemiplimab and chemotherapy continues to enroll well, with an interim futility analysis expected later this year. Management acknowledged that the recent approval of a competing KRAS-targeted therapy could affect the treatment landscape but said it still sees a role for CXCR4 inhibition.
- BioLineRx ended the quarter with $13.1 million in cash, expected to fund operations into the first half of 2027, but reported a $4.3 million quarterly net loss and announced a $3.75 million registered direct offering, which adds near-term dilution risk. APHEXDA generated $1.6 million in quarterly sales and $0.3 million in royalty revenue, although adoption remains dependent on gradually changing transplant-center practices.
BioLineRx Trading Down 1.4%
BLRX stock opened at $2.76 on Wednesday. The company has a market capitalization of $12.06 million, a PE ratio of -1.63 and a beta of 1.56. BioLineRx has a one year low of $2.15 and a one year high of $4.56. The company’s 50 day moving average price is $2.90 and its two-hundred day moving average price is $2.83. The company has a debt-to-equity ratio of 0.16, a quick ratio of 1.43 and a current ratio of 1.58.
Analysts Set New Price Targets
Get Our Latest Report on BioLineRx
About BioLineRx
BioLineRx (NASDAQ: BLRX) is a clinical-stage biopharmaceutical company that discovers and develops novel small-molecule therapies to address unmet medical needs. The company focuses on identifying promising drug candidates through licensing and collaboration agreements with academic institutions and biotech innovators, then advancing these candidates through preclinical and clinical development stages. BioLineRx’s pipeline spans oncology, immunology and inflammatory diseases, central nervous system disorders and pain management.
Among its clinical programs, BioLineRx is advancing targeted cancer therapies designed to improve outcomes for patients with difficult-to-treat tumors.
Recommended Stories
- Five stocks we like better than BioLineRx
- Dutch Bros Sell-Off Creates a Growth Opportunity
- NVIDIA’s MediaTek Bet Shows How It Plans to Defend Its AI Moat
- Is Abercrombie & Fitch’s Hot Streak Just Getting Started?
- Medtronic’s Stars Are Aligning for a Price Recovery
Receive News & Ratings for BioLineRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx and related companies with MarketBeat.com's FREE daily email newsletter.
